BIOMAT Database Logo BIOMAT Database Logo

Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. 2011

Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Department of Chemistry, Vertex Pharmaceuticals (Europe) Ltd., 88 Milton Park, Abingdon, Oxfordshire OX14 4RY, UK. jean-damien_charrier@vrtx.com

Interleukin-2 inducible T-cell kinase (Itk) plays a role in T-cell functions, and its inhibition potentially represents an attractive intervention point to treat autoimmune and allergic diseases. Herein we describe the discovery of a series of potent and selective novel inhibitors of Itk. These inhibitors were identified by structure-based design, starting from a fragment generated de novo, the 3-aminopyrid-2-one motif. Functionalization of the 3-amino group enabled rapid enhancement of the inhibitory activity against Itk, while introduction of a substituted heteroaromatic ring in position 5 of the pyridone fragment was key to achieving optimal selectivity over related kinases. A careful analysis of the hydration patterns in the kinase active site was necessary to fully explain the observed selectivity profile. The best molecule prepared in this optimization campaign, 7v, inhibits Itk with a K(i) of 7 nM and has a good selectivity profile across kinases.

UI MeSH Term Description Entries
D008301 Maleimides Derivatives of maleimide (the structural formula H2C2(CO)2NH) containing a pyrroledione ring where the hydrogen atom of the NH group is replaced with aliphatic or aromatic groups.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011505 Protein-Tyrosine Kinases Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors. Tyrosine Protein Kinase,Tyrosine-Specific Protein Kinase,Protein-Tyrosine Kinase,Tyrosine Kinase,Tyrosine Protein Kinases,Tyrosine-Specific Protein Kinases,Tyrosylprotein Kinase,Kinase, Protein-Tyrosine,Kinase, Tyrosine,Kinase, Tyrosine Protein,Kinase, Tyrosine-Specific Protein,Kinase, Tyrosylprotein,Kinases, Protein-Tyrosine,Kinases, Tyrosine Protein,Kinases, Tyrosine-Specific Protein,Protein Kinase, Tyrosine-Specific,Protein Kinases, Tyrosine,Protein Kinases, Tyrosine-Specific,Protein Tyrosine Kinase,Protein Tyrosine Kinases,Tyrosine Specific Protein Kinase,Tyrosine Specific Protein Kinases
D011728 Pyridones Pyridine derivatives with one or more keto groups on the ring. Pyridinones
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D047428 Protein Kinase Inhibitors Agents that inhibit PROTEIN KINASES. Protein Kinase Inhibitor,Inhibitor, Protein Kinase,Inhibitors, Protein Kinase,Kinase Inhibitor, Protein,Kinase Inhibitors, Protein

Related Publications

Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Discovery and optimization of indazoles as potent and selective interleukin-2 inducible T cell kinase (ITK) inhibitors.
June 2014, Bioorganic & medicinal chemistry letters,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
February 2020, European journal of medicinal chemistry,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
February 2009, Bioorganic & medicinal chemistry letters,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).
December 2013, Bioorganic & medicinal chemistry letters,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
July 2019, European journal of medicinal chemistry,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Interleukin-2-inducible T-cell kinase (Itk) signaling regulates potent noncanonical regulatory T cells.
December 2021, Clinical and translational medicine,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Discovery of Potent and Highly Selective Interleukin-2-Inducible T-Cell Kinase Degraders with In Vivo Activity.
April 2023, Journal of medicinal chemistry,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
December 2014, Bioorganic & medicinal chemistry letters,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Identification of inactive conformation-selective interleukin-2-inducible T-cell kinase (ITK) inhibitors based on second-harmonic generation.
September 2018, FEBS open bio,
Jean-Damien Charrier, and Andrew Miller, and David P Kay, and Guy Brenchley, and Heather C Twin, and Philip N Collier, and Sharn Ramaya, and Shazia B Keily, and Steven J Durrant, and Ronald M A Knegtel, and Adam J Tanner, and Kieron Brown, and Adam P Curnock, and Juan-Miguel Jimenez
Targeting Interleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.
June 2014, Postdoc journal : a journal of postdoctoral research and postdoctoral affairs,
Copied contents to your clipboard!